| 引用本文: | 陈文莉,韩大飞,何广卫,储昭兴.基于特应性皮炎严重程度的临床生物标志物研究进展[J].中国现代应用药学,2022,39(13):1762-1766. |
| CHEN Wenli,HAN Dafei,HE Guangwei,CHU Zhaoxing.Advances in Clinical Biomarkers Based on the Severity of Atopic Dermatitis[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(13):1762-1766. |
|
| 摘要: |
| 特应性皮炎（atopic dermatitis，AD）是一种慢性炎症性皮肤病，具有异质性的特点，临床根据AD轻、中、重度患者，采取不同的治疗方案。准确地判断出AD的严重程度对提出治疗方案极为重要，目前对于AD严重程度的判断还是依赖于特应性皮炎评分和湿疹面积和严重程度指数，这难以准确预测疾病的转归和复发。近年来，关于AD严重程度的临床生物标志物研究取得了一定的进展，研究主要集中在趋化因子类（如CCL17）、白细胞介素类（如IL-31、IL-17）等，本文从相关生物标志物与AD发病机制的关系及严重程度的相关性角度，总结了相关标志物的研究进展，希望为临床诊断及治疗提供一定的依据。 |
| 关键词: 特应性皮炎 生物标志物 严重程度 CCL17 IL-31 IL-17 |
| DOI：10.13748/j.cnki.issn1007-7693.2022.13.016 |
| 分类号:R969 |
| 基金项目:“重大新药创制”国家科技重大专项（2012ZX09401006） |
|
| Advances in Clinical Biomarkers Based on the Severity of Atopic Dermatitis |
|
CHEN Wenli1,2, HAN Dafei2, HE Guangwei2, CHU Zhaoxing2
|
|
1.Anhui University of Chinese Medicine, Hefei 230012, China;2.Hefei Institute of Pharmaceutical Industry Co., Ltd., Hefei 230601, China
|
| Abstract: |
| Atopic dermatitis(AD) is a chronic inflammatory skin disease with heterogeneous characteristics. Different treatment schemes are adopted according to mild, moderate and severe AD patients. It's significant to precise determination of the severity of AD for the proposal of treatment. Currently, the decision of severity still depends on scoring atopic dermatitis and eczema area and severity index. It is challenging to accurately predict the outcome and recurrence of the ailment. In recent years, research on clinical biomarkers of the severity of AD has made some development. The research mainly focuses on chemokines(such as CCL17), interleukins(such as IL-31, IL-17), etc. From the perspective of the relationship between biomarkers and the pathogenesis of AD and the degree of severity, the research progress of related markers is summarized, and it is hoped to provide a certain basis for clinical diagnosis and treatment. |
| Key words: atopic dermatitis biomarkers severity CCL17 IL-31 IL-17 |
